Lercanidipine HCl (REC 15-237, Lercadip, Lerdip, Zanidip)

Description: Lercanidipine HCl (REC-15-237, Lercadip, Lerdip, Zanidip) is a 3rd generation and lipophilic CCB (calcium channel blocker) of the dihydropyridine class and a medication used to treat high blood pressure, with long lasting antihypertensive action and reno-protective effect. It works by relaxing and opening the blood vessels allowing the blood to circulate more freely around the body. This lowers the blood pressure and allows the heart to work more efficiently.

References:

1. Barrios, V., et al., Lercanidipine is an effective and well tolerated antihypertensive drug regardless the cardiovascular risk profile: The LAURA study. Int J Clin Pract, 2006. 60(11): p. 1364-70.

2. Burnier, M., M. Pruijm, and G. Wuerzner, Treatment of essential hypertension with calcium channel blockers: what is the place of lercanidipine? Expert Opin Drug Metab Toxicol, 2009. 5(8): p. 981-7.

3. Grassi G, et, al. Lercanidipine in the Management of Hypertension: An Update. J Pharmacol Pharmacother. Oct-Dec 2017; 8(4):155-165.

4. Clinical efficacy of calcium channel blockers slow the third generation of lercanidipine in the treatment of patients with arterial hypertension and metabolic disorders (review). Georgian Med News. 2015 Feb; (239):51-6. Review. Russian.

Related CAS: 132866-11-6 (HCl) 100427-26-7 (free base)